GlassScriptPhysician profile
William W Kim
NPI 1407829385
$16,102.06
in general payments reported to CMS, 2019-2025
36 companies · $1,585 in 2025
The $1,585 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,267 · 2020: $2,999 · 2021: $2,830 · 2022: $899 · 2023: $1,568 · 2024: $1,954 · 2025: $1,585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,106.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,841.25 | 2019-2025 | |
| Amgen INC. | $1,589.34 | 2019-2025 | Otezla, Uplizna |
| Ucb, INC. | $1,180.92 | 2019-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $904.99 | 2019-2021 | |
| Pfizer INC. | $708.34 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $592.80 | 2019-2021 | |
| Janssen Biotech, INC. | $552.46 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $518.58 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $494.07 | 2023-2025 | Relistor |
| Glaxosmithkline, LLC. | $437.47 | 2019-2021 | |
| Genzyme Corporation | $425.47 | 2019-2025 | |
| Lilly USA, LLC | $388.18 | 2020-2023 | Taltz |
| Genentech USA, INC. | $374.00 | 2019-2021 | |
| Horizon Therapeutics Plc | $265.79 | 2019-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.00 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $221.77 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $169.61 | 2021-2024 | Saphnelo |
| Radius Health, INC. | $157.33 | 2020-2024 | Tymlos |
| Nevro Corp. | $138.29 | 2023 | Senza |
| Ani Pharmaceuticals, INC. | $125.00 | 2023 | Purified Cortrophin Gel |
| Alexion Pharmaceuticals, INC. | $121.96 | 2023 | |
| Aurinia Pharma U.S., INC. | $121.90 | 2021 | |
| Cardinal Health 110 LLC | $100.00 | 2021 | |
| Scilex Pharmaceuticals INC. | $95.93 | 2024-2025 | |
| Mallinckrodt Enterprises LLC | $68.34 | 2019 | |
| Ibsa Pharma INC. | $65.87 | 2024-2025 | Tirosint, Licart, Flector |
| Collegium Pharmaceutical, INC. | $58.32 | 2024 | Belbuca, Nucynta |
| Celgene Corporation | $35.35 | 2019 | |
| Merck Sharp & Dohme LLC | $31.45 | 2020-2021 | |
| Azurity Pharmaceuticals, INC. | $19.65 | 2024 | Horizant |
| Sanofi-Aventis U.S. LLC | $18.62 | 2019 | |
| Pacira Therapeutics, INC. | $14.81 | 2019 | |
| Sobi, INC | $12.98 | 2019 | |
| Organon LLC | $5.22 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.